Advertisement
Document › Details
Sygnis AG. (4/24/17). "Press Release: Sygnis AG Expands Access to Chinese Market with Second OEM Deal with Tanon". Madrid & Heidelberg.
Region | China | |
Organisation | Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) | |
Group | 2invest (Group) | |
Organisation 2 | Tanon Science & Technology Co., Ltd. | |
Product | proteomic technology | |
Product 2 | immunoblot | |
Person | Lanckriet, Heikki (Expedeon 201111 CEO + Founder) | |
Person 2 | de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia) | |
• Current OEM agreement expanded to cover two additional product lines
• Expected annual revenue contribution now more than EUR 1M
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the successful completion of a second contract with TANON, the leading Chinese proteomics company. The OEM deal expands the current agreement, granting the rights to sell three SYGNIS product lines. The earlier agreement, which covered precast gels, now adds InstantBlue for easy protein detection and Ultrafast blotting buffer for Western Blotting (a widely used analytical technique used to detect specific proteins in a sample). Under the terms of the new agreement, TANON will sell the SYGNIS products under the TANON label to the Chinese market. This arrangement will enable TANON to deliver a more comprehensive solution to its customers, underpinning proteomics research. With this new agreement, the annual revenues from the TANON relationship are expected to exceed EUR 1M. Expedeon, which was acquired by SYGNIS in 2016, closed the earlier deal with TANON in December 2015.
Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS, said: “With life sciences research activities increasing significantly in China, we have seen a heightened interest in and need for our cutting-edge reagents and kits, making China a key market for SYGNIS. The expanded deal with TANON is expected to contribute to growing revenues and, ultimately, achieving profitability.”
Pilar de la Huerta, Co-CEO and CBDO of SYGNIS, added: “China is a challenging market to enter. TANON is a well-known proteomics player in China and has a strong customer base in the right segments for SYGNIS’ products. Already from the start, our cooperation was very successful. TANON has proved to be a partner with an ideal fit and we are very pleased to extend the cooperation with this second agreement.”
Cheng Wei Meng, CEO of TANON, noted: “We are delighted to be strengthening our relationship with SYGNIS. The technology and product offering afforded by this partnership have been extremely well received by our Chinese customer base. We see real opportunities to extend this relationship further in the future.”
For further information, please contact:
SYGNIS AG
Dr. Heikki Lanckriet
Co-CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com
Pilar de la Huerta
Co-CEO/CBDO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, in July 2016, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S. provider of Life Sciences tools C.B.S. Scientific in December 2016. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
About TANON: www.biotanon.com
TANON Science & Technology Co., Ltd. was founded in the early ninety's, specializing in the field of development, production and marketing of the electrophoresis system and the software run with life sciences. With the combination of independent research and development, international cooperation and introduction, TANON dedicates to manufacture the highest quality products at the competitive prices and provide the advanced tool to the researchers who are engaged in the field of molecular biology.
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
Madrid, Spain/Heidelberg, Germany
SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany, www.sygnis.de, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127
Record changed: 2023-06-05 |
Advertisement
More documents for 2invest (Group)
- [1] 4basebio AG. (7/28/20). "Press Release: 4basebio Informs about Takeover Bid by Sparta AG". Heidelberg & Cambridge....
- [2] Expedeon AG. (11/11/19). "Press Release: Expedeon AG Signs EUR 120 Million Deal with Abcam for the Sale of Its immunology and Proteomics Business". Heidelberg & Cambridge....
- [3] Expedeon AG. (8/6/19). "Press Release: Expedeon AG Signs Commercial Agreement with Sona Nanotech". Halifax, Heidelberg & Cambridge....
- [4] Sygnis AG. (5/8/18). "Press Release: Sygnis Completes Acquisition of TGR Biosciences". Heidelberg & Cambridge....
- [5] Sygnis AG. (10/24/17). "Press Release: Sygnis AG Announces the Launch of the Universal Lateral Flow Assay Kit and Associated Patent Filing". Madrid & Heidelberg....
- [6] Sygnis AG. (8/3/17). "Press Release: Sygnis AG Reports Financial Results for the Second Quarter and First Six Months of 2017". Madrid & Heidelberg....
- [7] Sygnis AG. (6/6/17). "Press Release: Sygnis AG Announces Management and Supervisory Board Changes. Dr. Heikki Lanckriet Sole CEO". Madrid & Heidelberg....
- [8] Sygnis AG. (5/8/17). "Press Release: Sygnis AG Plans to Acquire Profitable Innova Biosciences Ltd. for EUR 8 Million in Cash and up to 3.5 Million Shares [Not for USA, Canada, Japan and Australia]". Madrid & Heidelberg....
- [9] Sygnis AG. (4/27/17). "Press Release: Sygnis AG Reports Financial Results for Fiscal Year 2016". Madrid & Heidelberg....
- [10] Sygnis AG. (4/11/17). "Press Release: Sygnis AG Successfully Completes Integration of Recently Acquired C.B.S. Scientific". Madrid & Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top